Adherence, Diversion, & Misuse

This fact sheet includes a basic description of opioids, a brief explanation of the risks, ways to prevent misuse, and strategies to helped loved ones who may be struggling with substance use disorder.

This fact sheet includes a basic description of stimulants, a brief explanation of the risks, ways to prevent misuse, and strategies to helped loved ones who may be struggling with substance use disorder.

This fact sheet includes a basic description of fentanyl, a brief explanation of the danger, and strategies to helped loved ones who may be using or at risk of using fentanyl.

This handout is designed to assist both newly formed and seasoned prevention coalitions to determine the who, what, and how to reduce health disparities as they implement substance misuse prevention programs.

Part 2 of this two-part series features a panel presentation of experts discussing how and why the system of inequity exists. Panelists share the fundamental causes of health disparities and recommendations to the field on responding to health disparities in substance misuse prevention.

Part 1 of this two-part series begins to explore why health equity matters in prevention, and uncover how culture and personal bias influence substance misuse prevention work.

This guide focuses on using medication-assisted treatment for opioid use disorder in jails and prisons and during the reentry process when justice-involved persons return to the community. 

This Topic Brief provides an overview of what constitutes low-threshold treatment for patients with OUD, the state of the evidence and patient perspectives on low-threshold OUD treatment, and key steps and strategies for providing low-threshold treatment for patients with OUD in primary care settings.

This web page is a resource center for social media, video, print, radio, FAQs, messaging, and other marketing materials that can be used to promote the 988 Suicide & Crisis Lifeline. It is designed for states, territories, tribes, crisis centers, communities, emergency service providers, and other partners to speak with one voice.

This public meeting explored real-world experiences and scientific evidence on emerging data trends for human xylazine exposure and examined concrete strategies for drug development and clinical research.